Verrica Pharmaceuticals Shares Are Trading Lower After the Company Announced a Structuring to Reduce Costs and Expand Access to YCANTH for the Treatment of Molluscum Contagiosum. Also, Brookline Capital Downgraded the Stock From Buy to Hold.
Verrica Pharmaceuticals Shares Are Trading Lower After the Company Announced a Structuring to Reduce Costs and Expand Access to YCANTH for the Treatment of Molluscum Contagiosum. Also, Brookline Capital Downgraded the Stock From Buy to Hold.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.